← Leaderboards
David T Curiel
University Of Alabama At Birmingham
$31,690,411
Attributed
$39,185,628
Total exposure
34
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,400,713 · 35
By mechanism
R01$20,032,922 · 14
UG3$4,781,793 · 2
UH3$4,001,694 · 1
P01$2,852,039 · 3
R21$2,170,242 · 5
R33$1,519,211 · 1
Top collaborators
- Steven Carl George7 shared
- Stacey Lynn Rentschler7 shared
- J Michael Mathis5 shared
- Michael R. Farzan2 shared
- Mauricio De Aguiar Martins2 shared
- Charles Bix Shoemaker2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- John Michael Ruppert$5,190,544
- Xiaoyun Wu$1,640,717
- Qiana L Matthews$1,443,025
- Suzanne M. Michalek$6,713,138
- Adrie Jc Steyn$19,209,171
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyAdenovirusesBaseVectorCapsidCellsAdenovirus VectorTransfection /Expression VectorDesignGenesAdenoviridaeGene DeliveryClinical TrialsTechnologyBiological ModelsIn VivoGeneticGene ExpressionParticleTumorComplexSpecificityNovel StrategiesVirion
Grant awards (133)
Vectored HIV Immunotherapy via in vivo B cell editing$1,272,001
R01 · FY2025 · AI · contact PI
Vectored HIV Immunotherapy via in vivo B cell editing$1,289,517
R01 · FY2024 · AI · contact PI
A Novel Vector Platform to Actualize T Cell Modification In Vivo$427,625
R21 · FY2023 · EB · contact PI
Novel Vector Platform for Gene Therapy$370,126
R01 · FY2022 · EB · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$1,065,481
UH3 · FY2021 · HL
Endothelial-targeted adenovirus for organ-selective gene editing in vivo$741,071
UG3 · FY2021 · TR · contact PI
Novel Vector Platform for Gene Therapy$422,338
R01 · FY2021 · EB · contact PI
Novel Vector Platform for Gene Therapy$353,902
R01 · FY2021 · EB · contact PI
Novel targeted adenovirus$348,844
R01 · FY2021 · CA · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$1,087,505
UH3 · FY2020 · HL
Endothelial-targeted adenovirus for organ-selective gene editing in vivo$753,385
UG3 · FY2020 · TR · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$723,616
UH3 · FY2020 · HL
Novel Vector Platform for Gene Therapy$360,535
R01 · FY2020 · EB · contact PI
Novel targeted adenovirus$348,844
R01 · FY2020 · CA · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$1,125,092
UH3 · FY2019 · HL
Endothelial-targeted adenovirus for organ-selective gene editing in vivo$715,145
UG3 · FY2019 · TR · contact PI
Novel Vector Platform for Gene Therapy$373,163
R01 · FY2019 · EB · contact PI
Novel targeted adenovirus$338,378
R01 · FY2019 · CA · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$1,136,669
UG3 · FY2018 · HL
Novel targeted adenovirus$348,844
R01 · FY2018 · CA · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$286,365
UG3 · FY2018 · HL
GORILLA ADENOVIRUS ZIKA VACCINE FOR HUMANS$228,750
R21 · FY2018 · AI · contact PI
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION$1,149,158
UG3 · FY2017 · HL
Novel targeted adenovirus$348,844
R01 · FY2017 · CA · contact PI
In Vivo Editing for Hemophilia Gene Therapy$215,085
R41 · FY2017 · TR · contact PI
GORILLA ADENOVIRUS ZIKA VACCINE FOR HUMANS$190,625
R21 · FY2017 · AI · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$469,520
R01 · FY2015 · CA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$460,508
R01 · FY2014 · CA · contact PI
Development of Oncolytic Adenovirus Targeting Pancreatic Cancer Stem Cells$149,229
P50 · FY2014 · CA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$449,047
R01 · FY2013 · CA · contact PI
Motor neuron-targeted adenovirus antidotes for botulism$231,510
R21 · FY2013 · AI
A GENE-THERAPY BASED FUNCTIONAL RESTORATION OF SALIVARY GLANDS$182,400
R21 · FY2013 · DE · contact PI
Development of Oncolytic Adenovirus Targeting Pancreatic Cancer Stem Cells$151,065
P50 · FY2013 · CA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$472,780
R01 · FY2012 · CA · contact PI
A GENE-THERAPY BASED FUNCTIONAL RESTORATION OF SALIVARY GLANDS$228,000
R21 · FY2012 · DE · contact PI
Motor neuron-targeted adenovirus antidotes for botulism$208,606
R21 · FY2012 · AI
Development of Oncolytic Adenovirus Targeting Pancreatic Cancer Stem Cells$163,881
P50 · FY2012 · CA · contact PI
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors$517,924
R01 · FY2011 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$361,151
R33 · FY2011 · AI · contact PI
Monitoring of advanced virotherapy for ovarian cancer$280,136
R01 · FY2011 · CA · contact PI
Development of Oncolytic Adenovirus Targeting Pancreatic Cancer Stem Cells$158,484
P50 · FY2011 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$426,217
R33 · FY2010 · AI · contact PI
Development of double-targeted vectors for long-term vascular expression in vivo$331,345
R01 · FY2010 · HL · contact PI
Development of double-targeted vectors for long-term vascular expression in vivo$279,730
R01 · FY2010 · HL · contact PI
Monitoring of advanced virotherapy for ovarian cancer$240,842
R01 · FY2010 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$234,967
R33 · FY2010 · AI · contact PI
Development of Oncolytic Adenovirus Targeting Pancreatic Cancer Stem Cells$169,407
P50 · FY2010 · CA · contact PI
Monitoring of advanced virotherapy for ovarian cancer$45,749
R01 · FY2010 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$18,406
R33 · FY2010 · AI · contact PI
Development of double-targeted vectors for long-term vascular expression in vivo$586,759
R01 · FY2009 · HL · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$478,470
R33 · FY2009 · AI · contact PI
Monitoring of advanced virotherapy for ovarian cancer$344,729
R01 · FY2009 · CA · contact PI
MDA-7/IL-24: Therapy of Ovarian Cancer$338,625
P01 · FY2009 · CA · contact PI
Monitoring of advanced virotherapy for ovarian cancer$296,250
R01 · FY2009 · CA · contact PI
Monitoring of advanced virotherapy for ovarian cancer$275,500
R01 · FY2009 · CA · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$262,662
R01 · FY2009 · CA · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$136,311
R01 · FY2009 · CA · contact PI
Core--Viral Vector$109,577
P01 · FY2009 · CA · contact PI
VISUALIZING GOLD-LABELED ADENOVIRAL VECTORS INSIDE CANCER CELLS$15,584
P41 · FY2009 · RR · contact PI
MDA-7/IL-24: Therapy of Ovarian Cancer$332,546
P01 · FY2008 · CA · contact PI
Monitoring of advanced virotherapy for ovarian cancer$275,500
R01 · FY2008 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$267,993
R21 · FY2008 · AI · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$262,662
R01 · FY2008 · CA · contact PI
Replicative adenoviruses with enhanced infectivity$247,476
R01 · FY2008 · CA · contact PI
Cancer Gene Therapy Training Program$183,164
T32 · FY2008 · CA · contact PI
CORE E- VECTOR DEVELOPMENT SUPPORT$157,712
P01 · FY2008 · HL · contact PI
Core--Viral Vector$107,756
P01 · FY2008 · CA · contact PI
VISUALIZING GOLD-LABELED ADENOVIRAL VECTORS INSIDE CANCER CELLS$9,756
P41 · FY2008 · RR · contact PI
MDA-7/IL-24: Therapy of Ovarian Cancer$352,943
P01 · FY2007 · CA · contact PI
Monitoring of advanced virotherapy for ovarian cancer$272,422
R01 · FY2007 · CA · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$262,662
R01 · FY2007 · CA · contact PI
Replicative adenoviruses with enhanced infectivity$247,476
R01 · FY2007 · CA · contact PI
Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach$204,733
R21 · FY2007 · AI · contact PI
Cancer Gene Therapy Training Program$188,651
T32 · FY2007 · CA · contact PI
CORE E- VECTOR DEVELOPMENT SUPPORT$156,499
P01 · FY2007 · HL · contact PI
Core--Viral Vector$115,285
P01 · FY2007 · CA · contact PI
MDA-7/IL-24: Therapy of Ovarian Cancer$277,413
P01 · FY2006 · CA · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$270,508
R01 · FY2006 · CA · contact PI
Replicative adenoviruses with enhanced infectivity$254,867
R01 · FY2006 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$252,035
R01 · FY2006 · CA · contact PI
CORE E- VECTOR DEVELOPMENT SUPPORT$152,900
P01 · FY2006 · HL · contact PI
Cancer Gene Therapy Training Program$92,674
T32 · FY2006 · CA · contact PI
Core--Viral Vector$90,562
P01 · FY2006 · CA · contact PI
Capsid-labeled adenovirus for virotherapy monitoring$283,651
R01 · FY2005 · CA
MDA-7/IL-24: Therapy of Ovarian Cancer$278,455
P01 · FY2005 · CA
Replicative adenoviruses with enhanced infectivity$261,000
R01 · FY2005 · CA
Enhanced CRAd for Pancreatic Cancer$258,100
R01 · FY2005 · CA
CORE E- VECTOR DEVELOPMENT SUPPORT$148,892
P01 · FY2005 · HL
Cancer Gene Therapy Training Program$139,861
T32 · FY2005 · CA
Core--Viral Vector$87,874
P01 · FY2005 · CA
Endothelial Gene Delivery for Pulmonary Hypertension$397,150
R01 · FY2004 · HL
Replicative adenoviruses with enhanced infectivity$261,000
R01 · FY2004 · CA
Enhanced CRAd for Pancreatic Cancer$258,100
R01 · FY2004 · CA
DENDRITIC CELL SPECIFIC VECTOR$226,013
R01 · FY2004 · CA
Cancer Gene Therapy Training Program$153,773
T32 · FY2004 · CA
CORE E- VECTOR DEVELOPMENT SUPPORT$145,000
P01 · FY2004 · HL
Endothelial Gene Delivery for Pulmonary Hypertension$385,581
R01 · FY2003 · HL
Enhanced CRAd for Pancreatic Cancer$258,100
R01 · FY2003 · CA
DENDRITIC CELL SPECIFIC VECTOR$226,013
R01 · FY2003 · CA
REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY$225,331
R01 · FY2003 · EB
Endothelial Gene Delivery for Pulmonary Hypertension$374,352
R01 · FY2002 · HL
Enhanced CRAd for Pancreatic Cancer$257,581
R01 · FY2002 · CA
DENDRITIC CELL SPECIFIC VECTOR$226,013
R01 · FY2002 · CA
REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY$219,509
R01 · FY2002 · CA
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$172,411
U19 · FY2002 · DK
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$172,411
U19 · FY2002 · DK
CANCER GENE THERAPY TRAINING PROGRAM$144,494
T32 · FY2002 · CA
Gene therapy program$0
P50 · FY2002 · CA
GENE THERAPY SPECIFICALLY DIRECTED AT TUMOR VASCULATURE$0
P50 · FY2002 · CA
Gene therapy program$0
P50 · FY2002 · CA
Gene therapy program$0
P50 · FY2002 · CA
Endothelial Gene Delivery for Pulmonary Hypertension$376,851
R01 · FY2001 · HL
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$296,752
U19 · FY2001 · DK
DENDRITIC CELL SPECIFIC VECTOR$226,013
R01 · FY2001 · CA
REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY$213,740
R01 · FY2001 · CA
ADENOVIRAL MEDIATED TARGETED GENE DELIVERY$210,414
R01 · FY2001 · CA
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$172,411
U19 · FY2001 · DK
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$172,411
U19 · FY2001 · DK
CANCER GENE THERAPY TRAINING PROGRAM$100,925
T32 · FY2001 · CA
Gene therapy program$0
P50 · FY2001 · CA
GENE THERAPY SPECIFICALLY DIRECTED AT TUMOR VASCULATURE$0
P50 · FY2001 · CA
Gene therapy program$0
P50 · FY2001 · CA
GENETIC MODIFICATION OF DENDRITIC CELLS FOR TOLERANCE$446,968
U19 · FY2000 · DK
TARGETED VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$266,321
R01 · FY2000 · HL
DENDRITIC CELL SPECIFIC VECTOR$226,013
R01 · FY2000 · CA
REPLICATIVE ADENOVIRUSES WITH ENHANCED INFECTIVITY$220,198
R01 · FY2000 · CA
NOVEL TECHNOLOGIES FOR NONINVASIVE DETECTION, DIAGNOSIS$218,430
N01 · FY2000 · CO
ADENOVIRAL MEDIATED TARGETED GENE DELIVERY$205,142
R01 · FY2000 · CA
CANCER GENE THERAPY TRAINING PROGRAM$124,000
T32 · FY2000 · CA
Gene therapy program$76,995
P50 · FY2000 · CA
Gene therapy program$76,995
P50 · FY2000 · CA
Gene therapy program$76,995
P50 · FY2000 · CA
GENE THERAPY SPECIFICALLY DIRECTED AT TUMOR VASCULATURE$0
P50 · FY2000 · CA